Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation.
Antioxidants
/ pharmacology
Cell Line, Tumor
Cisplatin
/ pharmacology
Drug Resistance, Neoplasm
/ genetics
Epithelial Cell Adhesion Molecule
/ metabolism
Gene Expression Regulation, Neoplastic
/ drug effects
Head and Neck Neoplasms
/ genetics
Humans
Interleukin-6
/ metabolism
Kelch-Like ECH-Associated Protein 1
/ metabolism
NF-E2-Related Factor 2
/ metabolism
RNA-Binding Proteins
/ metabolism
Reactive Oxygen Species
/ metabolism
SOXB1 Transcription Factors
Signal Transduction
/ drug effects
Squamous Cell Carcinoma of Head and Neck
/ genetics
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
20 08 2020
20 08 2020
Historique:
received:
20
02
2020
accepted:
05
08
2020
revised:
05
08
2020
entrez:
21
8
2020
pubmed:
21
8
2020
medline:
14
4
2021
Statut:
epublish
Résumé
Overexpression of epithelial cell adhesion molecule (EpCAM) has been associated with chemotherapeutic resistance, leads to aggressive tumor behavior, and results in an adverse clinical outcome. The molecular mechanism by which EpCAM enrichment is linked to therapeutic resistance via Nrf2, a key regulator of antioxidant genes is unknown. We have investigated the link between EpCAM and the Nrf2 pathway in light of therapeutic resistance using head and neck squamous cell carcinoma (HNSCC) patient tumor samples and cell lines. We report that EpCAM was highly expressed in Nrf2-positive and HPV-negative HNSCC cells. In addition, cisplatin-resistant tumor cells consisted of a higher proportion of EpCAM
Identifiants
pubmed: 32814771
doi: 10.1038/s41419-020-02907-x
pii: 10.1038/s41419-020-02907-x
pmc: PMC7438524
doi:
Substances chimiques
Antioxidants
0
EPCAM protein, human
0
Epithelial Cell Adhesion Molecule
0
Interleukin-6
0
Kelch-Like ECH-Associated Protein 1
0
NF-E2-Related Factor 2
0
NFE2L2 protein, human
0
P62 protein, human
0
RNA-Binding Proteins
0
Reactive Oxygen Species
0
SOX2 protein, human
0
SOXB1 Transcription Factors
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
663Références
Bray et al. Global cancer statistics 2028: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
pubmed: 30207593
pmcid: 30207593
Siegel, R., Nalshadham, D. & Jemal, A. Cancer statistics, 2018 CA. Cancer J. Clin. 68, 7–30 (2018).
doi: 10.3322/caac.21442
Lopez-Verdin, S. et al. Molecular markers of anticancer drug resistance in head and neck squamous cell carcinoma. Cancer 10, 376 (2018).
doi: 10.3390/cancers10100376
Jaramillo, M. C. & Zhang, D. D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 77, 2179–2191 (2013).
doi: 10.1101/gad.225680.113
Hayes, J. D. & McMahon, M. Nrf2 and Keap1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 34, 76–188 (2009).
doi: 10.1016/j.tibs.2008.12.008
Singh, A. et al. RNAi-mediated silencing of nuclear factor erythroid-2 related factor 2 gene expression in non-small cell lung cancer tumor growth and increase efficacy of chemotherapy. Cancer Res. 68, 7975–7984 (2008).
doi: 10.1158/0008-5472.CAN-08-1401
Alison, M. R., Islam, S. & Wright, N. A. Stem cells in cancer: instigator and propagators? J. Cell Sci. 123, 2357–2368 (2010).
doi: 10.1242/jcs.054296
Frank, N. Y., Schatton, T. & Frank, M. H. The therapeutic promise of the cancer stem cells concept. J. Clin. Invest. 120, 41–50 (2010).
doi: 10.1172/JCI41004
Prieti-Vila, M., Takahashi, R., Usuba, W., Kohama, I. & Ochiya, T. Drug resistance driven by cancer stem cells and their niche. Int. J. Mol. Sci. 18, 2574 (2017).
doi: 10.3390/ijms18122574
Ryoo, I. G., Lee, S. H. & Kwak, M. K. Redox modulating Nrf2: a potential mediator of cancer stem cell resistance. Oxid. Med. Cell Longev. 2016, 2412853 (2016).
doi: 10.1155/2016/2428153
Ricardo, S. et al. Breast cancer stem cell markers CD44, Cd24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 64, 937–946 (2011).
doi: 10.1136/jcp.2011.090456
Ponti, D. et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506–5511 (2005).
doi: 10.1158/0008-5472.CAN-05-0626
Imrich, S., Hachmeister, M. & Gires, O. EpCAM and its potential role in tumor-initiating cell. Cell Adh. Migr. 6, 30–38 (2012).
doi: 10.4161/cam.18953
Benko, G., Spajic, B., Kruslin, B. & Tomas, D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol. Oncol. 31, 468–474 (2013).
doi: 10.1016/j.urolonc.2011.03.007
Ni, J. et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int. J. Biochem. Cell Biol. 45, 2736–2748 (2013).
doi: 10.1016/j.biocel.2013.09.008
Massoner, P. et al. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by EMT-associated miRNA-200c/205. Br. J. Cancer 111, 955–964 (2014).
doi: 10.1038/bjc.2014.366
Hiraga, T., Ito, S. & Nakamura, H. EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation. Int. J. Cancer 138, 1698–1708 (2016).
doi: 10.1002/ijc.29921
Patricia, C., Macchi, R. M. & Marchner, H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat. Rev. 38, 68–75 (2012).
doi: 10.1016/j.ctrv.2011.04.002
Zhu, J. et al. Nrf2 is required to maintain the self-renewal of glioma stem cells. BMC Cancer 13, 380 (2013).
doi: 10.1186/1471-2407-13-380
Ryoo, L. G., Kim, G., Choi, B. H., Lee, S. H. & Kwak, M. K. Involvement of Nrf2 signaling in doxorubicin resistance of cancer stem cell-enriched colonospheres. Biomol. Ther. 24, 482–488 (2016).
doi: 10.4062/biomolther.2016.145
Kim, D., Choi, B., Ryoo, I. G. & Kwak, M. K. High Nrf2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/Nrf2 signaling. Cell Death Dis. 9, 896 (2018).
doi: 10.1038/s41419-018-0903-4
Roh, J. L., Kim, E. H., Jang, H. & Shin, D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 11, 254–262 (2017).
doi: 10.1016/j.redox.2016.12.010
Braakhuis, B. J. et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J. Natl Cancer Inst. 96, 998–1006 (2004).
doi: 10.1093/jnci/djh183
Chen, D. et al. Targeting BMI-1+ cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma. Cell Stem Cell 20, 621–634 (2017).
doi: 10.1016/j.stem.2017.02.003
Masui, T. et al. Snail-induced epithelial-mesenchymal transition promotes cancer stem cell-like phenotype in head and neck cancer cells. Int. J. Oncol. 44, 693–699 (2014).
doi: 10.3892/ijo.2013.2225
Lopez-Verdin, S. et al. Molecular markers of anticancer drug resistance in head and neck squamous cell carcinoma: a literature review. Cancers 10, 376 (2018).
doi: 10.3390/cancers10100376
Shibata, T. et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135, 1358–1368 (2008).
doi: 10.1053/j.gastro.2008.06.082
Matsouka, Y. et al. IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidnat pathway in oral squamous cell carcinoma. Br. J. Cancer 115, 1234–1244 (2016).
doi: 10.1038/bjc.2016.327
Nakashima, H. et al. Pre-treatment neutrophil to lymphocyte ration predicts the chemotherapy outcome and survival in patients with oral squamous cell carcinoma: a retrospective study. BMC Cancer 16, 41 (2016).
doi: 10.1186/s12885-016-2079-6
Karkkainen, V. et al. Nrf2 regulates neurogenesis and protects neural progenitor cells against Aβ toxicity. Stem Cells 32, 1904–1916 (2014).
doi: 10.1002/stem.1666
Zhu, J. et al. Nrf2 is required to maintain the self -renewal of glioma stem cells. BMC Cancer 13, 380 (2013).
doi: 10.1186/1471-2407-13-380
Yanamoto, S. et al. Clinicopathological significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as potential target for tongue cancer gene therapy. Oral Oncol. 43, 869–877 (2007).
doi: 10.1016/j.oraloncology.2006.10.010
Soysal, S. D. et al. EpCAM expression varies significantly and differential associated with prognosis in the luminalB HER2+, basal-like, and HER2 intrinsic subtypes of breast cancer. Br. J. Cancer 108, 1480–1487 (2013).
doi: 10.1038/bjc.2013.80
Dong, C. et al. Loss of FBP1 by-snail mediated repression provides metabolic advantage in basal-like breast cancer. Cancer Cell 23, 316–331 (2013).
doi: 10.1016/j.ccr.2013.01.022
Achuthan, S., Santhoskumar, T. R., Prabakar, J., Nair, S. A. & Pillai, M. R. Drug induced senescence generates chemoresistant stem like cells with low reactive oxygen species. J. Biol. Chem. 86, 37813–37829 (2011).
doi: 10.1074/jbc.M110.200675
Ryoo, I. G., Choi, B. H. & Kwak, M. K. Activation of Nrf2 by p62 and proteasome reduction in sphere forming breast cancer cells. Oncotarget 6, 8167–8184 (2015).
doi: 10.18632/oncotarget.3047
Ryoo, I. G., Choi, B. H., Ku, S. K. & Kwak, M. K. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: implications for cancer stem cell resistance. Redox Biol. 17, 246–258 (2018).
doi: 10.1016/j.redox.2018.04.015
Yang, H. et al. The role of cellular reactive oxygen species in cancer chemotherapy. J. Exp. Clin. Cancer Res. 37, 266 (2018).
doi: 10.1186/s13046-018-0909-x
Chen, Y. et al. IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation. Radiat. Oncol. 10, 227 (2015).
doi: 10.1186/s13014-015-0534-1
Reiko, I. et al. High expression of p62 protein is associated with poor prognosis and aggressive phenotypes in endometrial cancer. Am. J. Pathol. 185, 2523–2533 (2015).
doi: 10.1016/j.ajpath.2015.05.008